



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

PATENT
Docket No.: 020885-000620US
Client Ref. Nos.: UC: 2003-143-3;
Stanford: S02-048

On 12-22-05

TOWNSEND and TOWNSEND and CREW LLP

By: Karen Karlin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Huda Akil et al.

Application No.: 10/701,263

Filed: November 3, 2003

For: COMPOSITIONS AND METHODS
FOR DIAGNOSING AND TREATING
MOOD DISORDERS

Examiner: Daniel E. Kolker

Art Unit: 1649

RESPONSE TO RESTRICTION
REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement mailed September 15, 2005, Applicants elect Group II, claims 1 (in part), 3-4, and 6-10 (in part), drawn to methods of determining whether a subject has or is predisposed for a mood disorder wherein the reagent is a nucleic acid. In addition, Applicants elect FGFR2 (M80634) as the single nucleic acid, and major depression disorder as the species.

The foregoing election is made with traverse, as the nine groups set forth by the Examiner all stem from a common concept and theory, and are thus related. As

Huda Akil et al.
Application No.: 10/701,263
Page 2

PATENT

such, prosecution of the claims of Groups I-IX would not place a substantially greater burden on the Examiner. Applicants therefore respectfully request that the Examiner withdraw the Restriction Requirement and consider all the claims together.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (925)-472-5000.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (925)-472-5000
Fax: (415) 576-0300
ASP:kk

60664879 v1